Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Oppenheimer lifted their FY2019 EPS estimates for shares of Crispr Therapeutics in a report issued on Monday, November 25th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan now expects that the company will post earnings per share of $0.59 for the year, up from their prior forecast of $0.58. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million.
Other analysts have also recently issued reports about the stock. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Roth Capital raised their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $69.54.
Shares of Crispr Therapeutics stock traded up $2.92 during midday trading on Wednesday, hitting $68.06. The company had a trading volume of 1,017,171 shares, compared to its average volume of 1,114,405. The company has a 50 day moving average of $62.13 and a 200 day moving average of $49.47. The stock has a market capitalization of $3.60 billion, a P/E ratio of -19.78 and a beta of 3.31. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
A number of hedge funds have recently modified their holdings of the business. NEXT Financial Group Inc increased its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares in the last quarter. Benjamin Edwards Inc. boosted its position in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at about $26,000. US Bancorp DE grew its stake in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares in the last quarter. Finally, BSW Wealth Partners purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at about $39,000. Institutional investors own 49.82% of the company’s stock.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. Corporate insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is meant by a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.